The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Join this session to discuss the challenges of and strategies for coordinating care for patients receiving therapies such as bispecific antibodies or chimeric antigen receptor (CAR) T-cell therapy in academic and community settings.
Learning Objectives:
Identify challenges associated with transitioning care from inpatient to outpatient in the setting of immunotherapy agents with risk of cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity (ICANS)
Discuss inpatient and outpatient CRS management of bispecific antibody therapies and indications for readmission
Demonstrate confidence in the management of bispecific antibody therapies in the community setting
Speaker(s):
Alisa
K. Heitman,
MSN, NP-C,
Manager of Advanced Practice Services,
University of Chicago Medical Center
Haleigh
Mistry,
MS, PA-C,
Physician Assistant,
UT MD Anderson Cancer Center
J. Brice
King,
MSN, APRN, FNP-C,
UT Health HOPE Cancer Center